Creatinine (mmol/l) Urea (mmol/l)
Treatment
     Plasma    urine     plasma       urine
D 0.26 ±0.03 2.64 ±0.46 11.23 ±0.49 473.33 ±81.5
 LevD 0.22 ± 0.03 8.09 ± 1.12b 16.63 ± 2.79 46.88 ± 12.2a
 LevDG 0.21 ± 0.02 10.23 ± 1.88 18.89 ± 1.30 38.31 ± 6.78
LevDM 0.19 ± 0.04 12.11 ± 1.46 18.46 ± 1.28 45.64 ± 5.03
LevDI20 0.18 ± 0.02 8.32 ± 2.04 16.54 ± 1.91 27.68 ± 4.26
LevDI40 0.26 ± 0.02 10.53 ± 3.06 17.90 ± 1.88 28.26 ± 6.89
Values are mean + SEM.
(n=5 per group).
ap<0.0001, bp<0.05 significantly different from the diabetic group .
D: Diabetic group
LevD: Potassium channel activated diabetic group
LevDG: Potassium channel activated diabetic group treated with glibenclamide
LevDM: Potassium channel activated diabetic group treated with metformin
LevDI20: Potassium channel activated diabetic group treated with 20 i.u/kg insulin
LevDI40 : Potassium channel activated diabetic group treated with 40 i.u/kg insulin
Table 2: The effects of levcromakalim on the creatinine and urea of streptozotocin-induced diabetic rats treated with glibenclamide (5 mg/kg), metformin (350 mg/kg) and insulin (5 & 10 i.u/kg).